Supernus Pharmaceuticals, Inc. (SUPN) Kelajakdagi narxning foydaga nisbati

supernus.com (SUPN) kompaniyasining rasmiy ramzlari

Supernus Pharmaceuticals (SUPN) nevrologik dori vositalarining yuqori marjasi hisobiga mustahkam likvidlik zaxirasini saqlab qolmoqda. Kompaniya Markaziy Nerv Tizimi (CNS) buzilishlarini davolash uchun keng qamrovli ekotizimni yaratmoqda va shifokorlar uchun asosiy hamkor sifatida o'z mavqeini mustahkamlamoqda. Emitentning forward P/E ko'rsatkichi kutilayotgan foyda nisbatidagi bozor baholash tendentsiyasini aks ettiradi, bunda 7.60 ushbu parametrning miqdorini belgilaydi. O'sish sur'atlari psixiatriya sektoridagi qat'iy FDA nazorati va yuqori patent talablari tufayli cheklangan.

SUPN - Supernus Prognoz qilingan narx-foyda nisbati 04.07.2022 - 16.11.2026 oraligʻida

Supernus (SUPN) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

Kompaniyaning har tomonlama tahlili:SUPN Supernus Corp
supernus.com brend mahsuloti

Forward P/E ko'rsatkichlari aksiyalar narxini prognoz qilingan sof foydaga nisbatan baholaydi, bu esa investorlarga kelajakdagi pul oqimlari asosida aktivning haddan tashqari sotib olingan holati darajasini aniqlash imkonini beradi. Supernus Pharmaceuticals (SUPN) kompaniyasining forward P/E ko'rsatkichini tahlil qilish orqali baholashning barqarorligini tasdiqlash mumkin, chunki nevrologik dori vositalari uchun diversifikatsiyalashgan taqsimot tizimi operatsion xatarlarni minimallashtiradi va daromadlar bashorat qilinuvchanligini ta'minlaydi.

Asosiy raqobatchilar

Forvard P/E multiplikatori BIIB|NBIX - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori RGC (Regencell Bioscience Ltd)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Kelajakdagi narxning foydaga nisbati|CPRX (Catalyst Pharmaceuticals) - Kelajakdagi narxning foydaga nisbati|DNLI (denalitherapeutics.com) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati HRMY (Harmony Biosciences Holdings, Inc.)|Forvard P/E multiplikatori BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Narxning kutilayotgan foydaga nisbati|anavex.com - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori CBLL (CeriBell, Inc.)|PRTA: Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati ALEC|ANNX (Annexon Biosciences Inc.) - Forvard P/E multiplikatori|omeros.com - Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Neurogene (NGNE)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati AC Immune SA|Forvard P/E multiplikatori VYGR (voyagertherapeutics.com)|Forvard P/E multiplikatori Neumora NMRA|Scilex Holding - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Tevogen Bio Inc.|Alpha Cognition (ACOG) - Kelajakdagi narxning foydaga nisbati|cogrx.com (CGTX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Inhibikase Therapeutics|Cassava (SAVA) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Assertio Therapeutics (ASRT)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Coya|Vistagen - Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori OVID|Acumen Pharmaceuticals Inc. - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati CervoMed Inc|ATHE: Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Clene Nanomedicine|Kelajakdagi narxning foydaga nisbati PepGen Corp|Jupiter Neurosciences (JUNS) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Relmada Therapeutics, Inc. (RLMD)|ANVS - Prognoz qilingan narx-foyda nisbati|gracetx.com - Prognoz qilingan narxning foydaga nisbati|AIFF: Narxning kelajakdagi foydaga nisbati|Klotho Neurosciences - Forvard P/E multiplikatori|NRSN (NeuroSense Therapeutics Ltd.) - Narxning kelajakdagi foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|MTVA (MetaVia Inc.) - Kelajakdagi narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati NeurAxis, Inc|Kelajakdagi narxning foydaga nisbati HSDT|Forvard P/E multiplikatori PASG|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Athira ATHA|Addex Therapeutics - Forvard P/E multiplikatori|ALZN - Forvard P/E multiplikatori|Cyclerion (CYCN) - Kelajakdagi narxning foydaga nisbati|Protagenic (PTIX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea|Narxning kelajakdagi foydaga nisbati CRGT (Cortigent)|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori CARA (Cara Therapeutics Inc)|CHRO - Prognoz qilingan narxning foydaga nisbati|ELYM: Prognoz qilingan narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Kelajakdagi narxning foydaga nisbati|Marinus - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati NKGen Biotech Inc|NRBO: Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati SAGE (Sage Therapeutics, Inc.)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neurotrope|Kelajakdagi narxning foydaga nisbati Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Prognoz qilingan narx-foyda nisbati|WENA: Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori CERE (Cerevel Therapeutics)